Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group (ECOG 1697) ME.10 -- Phase III Randomized Study of Four Weeks High Dose IFN-ALPHA2b in Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a,3 (Microscopic) Melanoma -- was closed to accrual effective Tuesday, October 26, 2010.

The Eastern Cooperative Oncology Group's Data Monitoring Committee met on 15 October 2010 and reviewed results of the third planned interim analysis for ME.10 (E1697).

Based on its review, the ECOG Data Monitoring Committee recommended the study be stopped because there is no evidence of benefit from treatment with interferon and no meaningful possibility that that the study will show a significant benefit from interferon.

Please see the ME.10 trial website for the trial closure letter and for other information regarding patient follow-up, etc.